BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 10521062)

  • 1. Oral fluoropyrimidines: a closer look at their toxicities.
    Macdonald JS
    Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oral chemotherapy agents.
    Royce ME; Hoff PM; Pazdur R
    Curr Oncol Rep; 2000 Jan; 2(1):31-7. PubMed ID: 11122822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral fluorouracil prodrugs.
    Pazdur R; Hoff PM; Medgyesy D; Royce M; Brito R
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):48-51. PubMed ID: 9830626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Answering patients' needs: oral alternatives to intravenous therapy.
    Borner M; Scheithauer W; Twelves C; Maroun J; Wilke H
    Oncologist; 2001; 6 Suppl 4():12-6. PubMed ID: 11585969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
    Cunningham D; James RD
    Eur J Cancer; 2001 May; 37(7):826-34. PubMed ID: 11313169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral therapy for colorectal cancer: how to choose.
    Damjanov N; Meropol NJ
    Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral versus intravenous fluoropyrimidines for colorectal cancer.
    Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral fluoropyrimidines: are they the equivalent of parenteral infusional 5-fluorouracil?
    Lokich J
    Cancer Invest; 2001; 19(8):854-7. PubMed ID: 11768039
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral fluoropyrimidines in the treatment of colorectal cancer.
    Meropol NJ
    Eur J Cancer; 1998 Sep; 34(10):1509-13. PubMed ID: 9893621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral fluoropyrimidine treatment of colorectal cancer.
    Eng C; Kindler HL; Schilsky RL
    Clin Colorectal Cancer; 2001 Aug; 1(2):95-103. PubMed ID: 12445367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
    Ward S; Kaltenthaler E; Cowan J; Brewer N
    Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oral fluoropyrimidines in oncology].
    González Barón M
    An R Acad Nac Med (Madr); 1998; 115(3):721-45; discussion 745-6. PubMed ID: 10208021
    [No Abstract]   [Full Text] [Related]  

  • 14. Colorectal cancer: chemotherapy treatment overview.
    Royce ME; Medgyesy D; Zukowski TH; Dwivedy S; Hoff PM; Pazdur R
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):40-6. PubMed ID: 11200148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
    Prescrire Int; 2002 Apr; 11(58):44-7. PubMed ID: 11987311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical considerations in the use of oral fluoropyrimidines.
    Hoff PM
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
    Nies AT; Magdy T; Schwab M; Zanger UM
    Adv Cancer Res; 2015; 125():217-43. PubMed ID: 25640272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
    Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK
    J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.